{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:09:18Z","timestamp":1791083358722,"version":"4.1.0"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.sxmr.2018.10.006","type":"journal-article","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T17:40:08Z","timestamp":1550943608000},"page":"259-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Testosterone and Benign Prostatic Hyperplasia"],"prefix":"10.1093","volume":"7","author":[{"given":"Giulia","family":"Rastrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vignozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2018.10.006_bib1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diff.2011.05.007","article-title":"The functional role of reactive stroma in benign prostatic hyperplasia","volume":"82","author":"Schauer","year":"2011","journal-title":"Differentiation"},{"key":"10.1016\/j.sxmr.2018.10.006_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0022-4731(81)90338-1","article-title":"Stromal-epithelial interactions, I: Induction of prostatic phenotype in urothelium of testicular feminized (Tfm\/y) mice","volume":"14","author":"Cunha","year":"1981","journal-title":"J\u00a0Steroid Biochem"},{"key":"10.1016\/j.sxmr.2018.10.006_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jemt.1070300407","article-title":"Instructive induction of prostate growth and differentiation by a defined urogenital sinus mesenchyme","volume":"30","author":"Timms","year":"1995","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.sxmr.2018.10.006_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/rep.0.1210187","article-title":"Role of androgens and fibroblast growth factors in prostatic development","volume":"121","author":"Thomson","year":"2001","journal-title":"Reproduction"},{"key":"10.1016\/j.sxmr.2018.10.006_bib5","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1210\/endo.132.6.7684975","article-title":"Assessment of prostatic protein secretion in tissue recombinants made of urogenital sinus mesenchyme and urothelium from normal or androgen-insensitive mice","volume":"132","author":"Donjacour","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.sxmr.2018.10.006_bib6","doi-asserted-by":"crossref","first-page":"14284","DOI":"10.1038\/ncomms14284","article-title":"Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing","volume":"8","author":"Xie","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.sxmr.2018.10.006_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ar.1091960302","article-title":"Correlation of early cytodifferentiation of the human fetal prostate and Leydig cells","volume":"196","author":"Kellokumpu-Lehtinen","year":"1980","journal-title":"Anat Rec"},{"key":"10.1016\/j.sxmr.2018.10.006_bib8","first-page":"465","article-title":"Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors","volume":"13","author":"Cunha","year":"1992","journal-title":"J\u00a0Androl"},{"key":"10.1016\/j.sxmr.2018.10.006_bib9","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1210\/jc.2007-1972","article-title":"Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study","volume":"93","author":"Wu","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2018.10.006_bib10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.urology.2007.05.025","article-title":"Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men","volume":"70","author":"Liu","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.10.006_bib11","first-page":"1309","article-title":"Relationship between benign prostatic hyperplasia\/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men","volume":"11","author":"Lee","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: The Saturation Model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib13","first-page":"2518","article-title":"Serum PSA as a predictor of testosterone deficiency","volume":"10","author":"Rastrelli","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.2011.10651.x","article-title":"Intraprostatic testosterone and dihydrotestosterone. Part I: Concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer","volume":"109","author":"van der Sluis","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib15","doi-asserted-by":"crossref","first-page":"E1577","DOI":"10.1210\/jc.2010-2216","article-title":"The relationships between sex hormones and sexual function in middle-aged and older European men","volume":"96","author":"O\u2019Connor","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2018.10.006_bib16","first-page":"2698","article-title":"Sex steroid receptors in male human bladder: Expression and biological function","volume":"7","author":"Chavalmane","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1749-6632.2009.04360.x","article-title":"The dual, opposing roles of estrogen in the prostate","volume":"1155","author":"Ellem","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.sxmr.2018.10.006_bib18","doi-asserted-by":"crossref","first-page":"15677","DOI":"10.1073\/pnas.95.26.15677","article-title":"Generation and reproductive phenotypes of mice lacking estrogen receptor beta","volume":"95","author":"Krege","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.sxmr.2018.10.006_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pros.22723","article-title":"Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: A role for GPR30\/GPER?","volume":"74","author":"Comeglio","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pros.20080","article-title":"Serum sex hormones and measures of benign prostatic hyperplasia","volume":"61","author":"Roberts","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1210\/jcem-73-5-1016","article-title":"Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study","volume":"73","author":"Gray","year":"1991","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2018.10.006_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/oxfordjournals.aje.a009519","article-title":"Sex hormones and age: A cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men","volume":"147","author":"Ferrini","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/pcan.2008.50","article-title":"Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia","volume":"12","author":"Hammarsten","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.sxmr.2018.10.006_bib24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.urology.2008.04.023","article-title":"Association between lower urinary tract symptoms and serum levels of sex hormones in men","volume":"72","author":"Miwa","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.10.006_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/pros.2990110404","article-title":"Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione","volume":"11","author":"Habenicht","year":"1987","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<199::AID-PROS1>3.0.CO;2-7","article-title":"Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group","volume":"29","author":"Radlmaier","year":"1996","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib27","first-page":"399","article-title":"Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group","volume":"154","author":"Gingell","year":"1995","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2265.2008.03327.x","article-title":"Effects of aromatase inhibition in hypogonadal older men: A randomized, double-blind, placebo-controlled trial","volume":"70","author":"Burnett-Bowie","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.sxmr.2018.10.006_bib29","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2003-031467","article-title":"Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels","volume":"89","author":"Leder","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2018.10.006_bib30","first-page":"29","article-title":"Androgen receptor content of nafoxidine-treated experimentally induced canine prostatic hyperplasia","volume":"8","author":"Trachtenberg","year":"1985","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1439-0531.2009.01379.x","article-title":"Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen","volume":"44","author":"Gonzalez","year":"2009","journal-title":"Reprod Domest Anim"},{"key":"10.1016\/j.sxmr.2018.10.006_bib32","first-page":"474","article-title":"The development of human benign prostatic hyperplasia with age","volume":"132","author":"Berry","year":"1984","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrurol.2015.301","article-title":"Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome","volume":"13","author":"Vignozzi","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000019749","article-title":"The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years","volume":"34","author":"Lee","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/01.LAB.0000081388.40145.65","article-title":"Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue","volume":"83","author":"Steiner","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.sxmr.2018.10.006_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/pros.10238","article-title":"Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate","volume":"56","author":"Steiner","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2605.2009.00972.x","article-title":"Chronic inflammation in the pathogenesis of benign prostatic hyperplasia","volume":"33","author":"Fibbi","year":"2009","journal-title":"Int J Androl"},{"key":"10.1016\/j.sxmr.2018.10.006_bib38","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.4049\/jimmunol.0801875","article-title":"Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation","volume":"182","author":"Penna","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/JOE-12-0142","article-title":"Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells","volume":"214","author":"Vignozzi","year":"2012","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41391-018-0041-1","article-title":"The microbiome in prostate inflammation and prostate cancer","volume":"21","author":"Porter","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.sxmr.2018.10.006_bib41","first-page":"454","article-title":"Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: Findings from the MTOPS Study","volume":"194","author":"Torkko","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib42","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.eururo.2007.11.026","article-title":"The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE Trial","volume":"54","author":"Nickel","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib43","first-page":"1493","article-title":"Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention","volume":"196","author":"Nickel","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib44","first-page":"122","article-title":"Chronic prostate inflammation predicts symptom progression in patients with chronic prostatitis\/chronic pelvic pain","volume":"198","author":"Nickel","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/bju.13334","article-title":"Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: A large, cross-sectional, UK epidemiological study","volume":"117","author":"DiBello","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bju.12728","article-title":"Metabolic syndrome and benign prostatic enlargement: A systematic review and meta-analysis","volume":"115","author":"Gacci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12894-017-0211-9","article-title":"Benign prostatic enlargement can be influenced by metabolic profile: Results of a multicenter prospective study","volume":"17","author":"Gacci","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib48","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bju.14007","article-title":"Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms (MIPS Study)","volume":"121","author":"Russo","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4103\/1008-682X.126382","article-title":"Clinical correlates of enlarged prostate size in subjects with sexual dysfunction","volume":"16","author":"Corona","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2018.10.006_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.4103\/1008-682X.122341","article-title":"Metabolic syndrome and prostate abnormalities in male subjects of infertile couples","volume":"16","author":"Lotti","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2018.10.006_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/aje\/kwp406","article-title":"Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results From the Prostate Cancer Prevention Trial","volume":"171","author":"Schenk","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib52","first-page":"3274","article-title":"Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome","volume":"6","author":"Filippi","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jsbmb.2012.02.007","article-title":"Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome","volume":"132","author":"Morelli","year":"2012","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/JOE-11-0289","article-title":"Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit","volume":"212","author":"Vignozzi","year":"2012","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib55","doi-asserted-by":"crossref","first-page":"329456","DOI":"10.1155\/2014\/329456","article-title":"Benign prostatic hyperplasia: A new metabolic disease of the aging male and its correlation with sexual dysfunctions","volume":"2014","author":"Corona","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/pros.22623","article-title":"Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation","volume":"73","author":"Vignozzi","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib57","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1158\/1940-6207.CAPR-17-0019","article-title":"Statin use, serum lipids, and prostate inflammation in men with a negative prostate biopsy: Results from the REDUCE Trial","volume":"10","author":"Allott","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.sxmr.2018.10.006_bib58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1464-410X.2010.09598.x","article-title":"Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms","volume":"107","author":"St Sauver","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annepidem.2010.09.002","article-title":"Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey","volume":"21","author":"Hall","year":"2011","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib60","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/aje\/kwt055","article-title":"A\u00a0prospective study of statin drug use and lower urinary tract symptoms in older men","volume":"178","author":"Mondul","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5414\/CP202033","article-title":"Statin-associated lower urinary tract symptoms: Data mining of the public version of the FDA adverse event reporting system, FAERS","volume":"52","author":"Fujimoto","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.sxmr.2018.10.006_bib62","doi-asserted-by":"crossref","first-page":"762","DOI":"10.5414\/CP202113","article-title":"Association of statin use with storage lower urinary tract symptoms (LUTS): Data mining of prescription database","volume":"52","author":"Fujimoto","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.sxmr.2018.10.006_bib63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2007.02.032","article-title":"Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement","volume":"52","author":"Mills","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib64","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1590\/S1677-55382008000500003","article-title":"The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride","volume":"34","author":"Stamatiou","year":"2018","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib65","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00345-015-1550-3","article-title":"The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome","volume":"33","author":"Zhang","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib66","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/aje\/kwn272","article-title":"Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the prostate cancer prevention trial","volume":"168","author":"Kristal","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib67","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/j.1464-410X.2009.09090.x","article-title":"Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men","volume":"105","author":"Trifiro","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib68","first-page":"130","article-title":"Members of the Florey Adelaide Male Ageing Study. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men","volume":"191","author":"Martin","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib69","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2010.05.026","article-title":"Androgens suppress antigen-specific T cell responses and IFN-\u03b3 production during intracranial LCMV infection","volume":"226","author":"Lin","year":"2010","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib71","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.4049\/jimmunol.173.10.6098","article-title":"Augmentation of T cell levels and responses induced by androgen deprivation","volume":"173","author":"Roden","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1095\/biolreprod.107.063545","article-title":"Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity","volume":"78","author":"Rettew","year":"2008","journal-title":"Biol Reprod"},{"key":"10.1016\/j.sxmr.2018.10.006_bib73","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.4049\/jimmunol.1001958","article-title":"Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: Evidence for a direct role of testosterone on regulatory T cell expansion","volume":"186","author":"Fijak","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib74","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1007\/s00296-011-2146-x","article-title":"Effects of testosterone, estrogen and progesterone on TNF-\u03b1 mediated cellular damage in rat arthritic synovial fibroblasts","volume":"32","author":"Ganesan","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib75","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.4049\/jimmunol.1400076","article-title":"Testosterone suppresses hepatic inflammation by the downregulation of IL-17, CXCL-9, and CXCL-10 in a mouse model of experimental acute cholangitis","volume":"194","author":"Schwinge","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4049\/jimmunol.159.1.3","article-title":"Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response","volume":"159","author":"Dalal","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib77","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00454.2015","article-title":"Low-dose testosterone protects against renal ischemia-reperfusion injury by increasing renal IL-10-to-TNF-\u03b1 ratio and attenuating T-cell infiltration","volume":"311","author":"Patil","year":"2016","journal-title":"Am J Physiol Physiol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib78","first-page":"557","article-title":"Hypogonadism and metabolic syndrome","volume":"34","author":"Corona","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.sxmr.2018.10.006_bib79","first-page":"9","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/13685530801953994","article-title":"Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study","volume":"11","author":"Kalinchenko","year":"2008","journal-title":"Aging Male"},{"key":"10.1016\/j.sxmr.2018.10.006_bib81","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0272.2008.00880.x","article-title":"Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men","volume":"41","author":"Haider","year":"2009","journal-title":"Andrologia"},{"key":"10.1016\/j.sxmr.2018.10.006_bib82","first-page":"257","article-title":"Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: Results from a propensity matched subgroup of a controlled registry study","volume":"199","author":"Haider","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib83","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.sxmr.2017.10.001","article-title":"Benefits and health implications of testosterone therapy in men with testosterone deficiency","volume":"6","author":"Traish","year":"2018","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.sxmr.2018.10.006_bib84","first-page":"1567","article-title":"Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life","volume":"11","author":"Yassin","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib85","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bju.13578","article-title":"Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: Prostate health outcomes in the Registry of Hypogonadism in Men","volume":"119","author":"Debruyne","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib86","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40618-016-0461-5","article-title":"Predictors and clinical consequences of starting androgen therapy in men with low testosterone: Results from the SIAMO-NOI registry","volume":"39","author":"Rastrelli","year":"2016","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.sxmr.2018.10.006_bib87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.urology.2013.08.019","article-title":"Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome","volume":"83","author":"Francomano","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2018.10.006_bib88","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.eururo.2016.01.043","article-title":"Effects of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and meta-analysis","volume":"69","author":"Kohn","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2018.10.006_bib89","first-page":"1092","article-title":"Effects of testosterone supplementation in the aging male","volume":"75","author":"Tenover","year":"1992","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2018.10.006_bib90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/pros.2990230203","article-title":"Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men","volume":"23","author":"Holm\u00e4ng","year":"1993","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2018.10.006_bib91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/13685530802290438","article-title":"The effect of testosterone therapy on lower urinary tract symptoms\/bladder and sexual functions in men with symptomatic late-onset hypogonadism","volume":"11","author":"Karazindiyano\u011flu","year":"2008","journal-title":"Aging Male"},{"key":"10.1016\/j.sxmr.2018.10.006_bib92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13685538.2010.518178","article-title":"Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study","volume":"14","author":"Shigehara","year":"2011","journal-title":"Aging Male"},{"key":"10.1016\/j.sxmr.2018.10.006_bib93","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","article-title":"Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial","volume":"296","author":"Marks","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2018.10.006_bib94","first-page":"S160","article-title":"Testosterone replacement therapy is able to reduce prostate inflammation in men with BPH, metabolic syndrome and hypogonadism: Preliminary results from a randomized placebo-controlled clinical trial","volume":"15","author":"Rastrelli","year":"2018","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2018.10.006_bib95","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1464-410X.2011.10652.x","article-title":"Intraprostatic testosterone and dihydrotestosterone. Part II: Concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer","volume":"109","author":"van der Sluis","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2018.10.006_bib96","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1055-9965.EPI-15-0987","article-title":"Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial","volume":"25","author":"Murtola","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118301434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052118301434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:21:45Z","timestamp":1694643705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052118301434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2050052118301434"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.10.006","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone and Benign Prostatic Hyperplasia","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Sexual Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}